Skip to main content
logo
Regencell Bioscience Holdings Limited (RGC)
NASDAQ: RGC · Real-Time Price · USD
10.05
+0.46 (4.80%)
Oct 19, 2026, 4:00 PM EDT - Market closed

RGC Income Statement

Millions USD. Fiscal year is Jul - Jun.
Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Jun '25 Jun '24 Jun '23 Jun '22
Selling, General & Admin
10.422.823.674.695.11
Research & Development
1.30.951.071.582.51
Operating Expenses
11.723.774.746.277.62
Operating Income
-11.72-3.77-4.74-6.27-7.62
EBT Excluding Unusual Items
-11.72-3.77-4.74-6.27-7.62
Other Unusual Items
0.020.190.370.210.02
Pretax Income
-11.7-3.58-4.36-6.06-7.59
Earnings From Continuing Operations
-11.7-3.58-4.36-6.06-7.59
Minority Interest in Earnings
--0.060.190.15
Net Income
-11.7-3.58-4.3-5.87-7.45
Net Income to Common
-11.7-3.58-4.3-5.87-7.45
Net Income Growth
-----
Shares Outstanding (Basic)
495494494494487
Shares Outstanding (Diluted)
495494494494487
Shares Change
0.02%--1.62%28.06%
EPS (Basic)
-0.02-0.01-0.01-0.01-0.02
EPS (Diluted)
-0.02-0.01-0.01-0.01-0.02
EPS Growth
-----

Additional Metrics

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Jun '25 Jun '24 Jun '23 Jun '22
Free Cash Flow
-7.7-3.27-4.01-4.99-6.05
Free Cash Flow Per Share
-0.02-0.01-0.01-0.01-0.01
EBITDA
-11.64-3.69-4.43-5.98-7.47
D&A For EBITDA
0.080.080.310.290.15
EBIT
-11.72-3.77-4.74-6.27-7.62
Advertising Expenses
--00.030.03
SEC Filings: 10-K · 10-Q